Autologous Platelet-Rich Plasma Eye Drops for the Treatment of Post-LASIK Chronic Ocular Surface Syndrome

Alió, Jorge L.; Rodrı́guez, Alejandra; Abdelghany, Ahmed A.; Oliveira, Renan F.

doi:10.1155/2017/2457620

Cited by 39 publications

(39 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its content of biologically active proteins, growth factors, and biomaterial scaffolds make PRP a therapeutic agent promoting ocular surface wound healing and regeneration (Anitua et al, 2016). PRP has also demonstrated efficacy, as a monotherapy, in the management of post laser refractive surgery 'ocular surface syndrome' (Alio et al, 2017).…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Neurotrophic keratopathy

Dua

Said

Messmer

et al. 2018

Progress in Retinal and Eye Research

289

356

View full text Add to dashboard Cite

Neurotrophic Keratopathy (NK) refers to a condition where corneal epitheliopathy leading to frank epithelial defect with or without stromal ulceration (melting) is associated with reduced or absent corneal sensations. Sensory nerves serve nociceptor and trophic functions, which can be affected independently or simultaneously. Loss of trophic function and consequent epithelial breakdown exposes the stroma making it susceptible to enzymatic degradation. Nerve pathology can range from attrition to aberrant re-generation with corresponding symptoms from anaesthesia to hyperaesthesia/allodynia. Many systemic and ocular conditions, including surgery and preserved medications can lead to NK. NK can be mild (epithelium and tear film changes), moderate (non-healing epithelial defect) or severe (stromal melting and perforation). Moderate and severe NK can profoundly affect vision and adversely impact on the quality of life. Medical management with lubricating agents from artificial tears to serum/plasma drops, anti-inflammatory agents, antibiotics and anti-proteases all provide non-specific relief, which may be temporary. Contact lenses, punctal plugs, lid closure with botulinum toxin and surgical interventions like tarsorrhaphy, conjunctival flaps and amniotic membrane provide greater success but often at the cost of obscuring sight. Corneal surgery in a dry ocular surface with reduced sensation is at high risk of failure. The recent advent of biologicals such as biopolymers mimicking heparan sulfate; coenzyme Q10 and antisense oligonucleotide that suppress connexin 43 expression, all offer promise. Recombinant nerve growth factor (cenegermin), recently approved for human use targets the nerve pathology and has the potential of addressing the underlying deficit and becoming a specific therapy for NK.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Neurotrophic keratopathy

Dua

Said

Messmer

et al. 2018

Progress in Retinal and Eye Research

289

356

View full text Add to dashboard Cite

show abstract

“…; Anitua ; Alio et al. ). Among these substances, the use of platelet‐rich plasma (PRP) has been extensively investigated for the treatment of several ocular surface conditions (Alio et al.…”

Section: Introductionmentioning

confidence: 99%

“…; Avila ; Anitua ; Alio et al. ). Platelet‐rich plasma (PRP) can be defined as a volume of AS containing a platelet concentration over the basal level (150 000–350 000/μl) (Wroblewski et al.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of treatment of hyposecretory dry eye with platelet‐rich plasma

Garcia-Conca

Abad-Collado²,

Hueso-Abancens

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

Objective: To evaluate and compare the symptomatology and clinical findings in hyposecretory dry eye of the treatment with platelet-rich plasma (PRP) and artificial tears of sodium hyaluronate (SH). Methods: Blind single-centre prospective comparative randomized study including 83 patients with hyposecretory dry eye and mean age of 64.0 years. Two groups were differentiated depending on the treatment applied: 44 patients treated with PRP (PRP group), and 39 patients treated with artificial tears of SH (SH group). Changes in Schimer test, tear osmolarity, corneal and conjunctival staining, tear film break-up time (TF-BUT), conjunctival hyperaemia, dry eye-related symptoms with the Ocular Surface Disease Index questionnaire, and caliciform cell density were evaluated during 30 days of treatment.Results: Significantly larger reduction in symptomatology (p < 0.001), visual improvement (p < 0.001), reduction in hyperaemia (p < 0.001), and corneal and conjunctival staining (p < 0.001), increment of Schirmer test outcome (p ≤ 0.005), and reduction of osmolarity were found in the PRP group in both eyes compared to SH group at 15 and 30 days of treatment. Likewise, a significantly higher increment of caliciform cell density (p < 0.001) was found in the PRP group. Strong and statistically significant correlations were found in the PRP group of the change achieved in visual acuity, hyperaemia, osmolarity, and conjunctival and corneal staining with the baseline values of these variables (p < 0.001). Conclusion: PRP treatment in hyposecretory dry eye induces a more significant positive effect over symptomatology and different dry eye signs than SH, especially in moderate and severe cases.

show abstract

“…The first descriptions of the development and use of PRP were in the early 1970s in the hematology field, followed by maxillofacial and oral surgery [ 3 ]. Subsequently, PRP has been used in a wide variety of disciplines, such as aesthetic dermatology [ 4 ], including alopecia [ 5 ] and skin rejuvenation [ 6 ]; the musculoskeletal field [ 7 ]; oral and maxillofacial surgery [ 8 ]; and ophthalmology [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Can Plasma Rich in Growth Factors Be Safe for Parental Use? A Safety Study in the Canine Model

Damia

Chicharro

Rubio

et al. 2018

IJMS

View full text Add to dashboard Cite

Low invasiveness is the main goal of modern surgery. The use of platelet-rich plasma (PRP) is known to be effective in a variety of applications, such as oral, maxillofacial, orthopedic, dermatologic and cosmetic surgeries. However, a potential ergogenic and carcinogenic effect of PRP derivatives by means of the insulin-like growth factor-1 (IGF-1) pathway has been suggested. Because of this notion, the purpose of this study is to assess the effect of a commercially available PRP-derivative intramuscular injection in the lumbar muscular tissue (local effect) and to determine the IGF-1 blood concentration (systemic effect) on healthy beagle dogs. Local effect was evaluated by computed tomography (CT) scan and echography, and systemic effect was calculated by blood testing on days 0, 14, 28, 42 and 56. No statistically significant changes were observed; thus, PRGF could be considered safe when using therapeutic doses.

show abstract

Autologous Platelet-Rich Plasma Eye Drops for the Treatment of Post-LASIK Chronic Ocular Surface Syndrome

Cited by 39 publications

References 31 publications

Neurotrophic keratopathy

Neurotrophic keratopathy

Efficacy and safety of treatment of hyposecretory dry eye with platelet‐rich plasma

Can Plasma Rich in Growth Factors Be Safe for Parental Use? A Safety Study in the Canine Model

Contact Info

Product

Resources

About